190 related articles for article (PubMed ID: 21647781)
21. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
Raju U; Fine G; Greenawald KA; Ohorodnik JM
Hum Pathol; 1989 May; 20(5):426-36. PubMed ID: 2707793
[TBL] [Abstract][Full Text] [Related]
22. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
23. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
24. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
25. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
27. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
29. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
[TBL] [Abstract][Full Text] [Related]
30. [Diagnosis and differential diagnosis of primary carcinoma of female peritoneum].
Wang M; Zhang TG; Xu C; Hou J; Li S
Zhonghua Bing Li Xue Za Zhi; 1999 Feb; 28(1):16-9. PubMed ID: 11869505
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
32. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Halperin R; Zehavi S; Hadas E; Habler L; Bukovsky I; Schneider D
Int J Gynecol Pathol; 2001 Oct; 20(4):341-5. PubMed ID: 11603217
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
36. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Zhang W; Wang L; Xin Z
Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal serous papillary adenocarcinoma: report of four cases.
Minami T; Nakatani K; Kondo S; Kanayama S; Tsujimura T
Intern Med; 2005 Sep; 44(9):944-8. PubMed ID: 16258208
[TBL] [Abstract][Full Text] [Related]
38. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
39. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
40. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]